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TO THE EDITOR
Linear IgA bullous dermatosis (LABD) is
defined by IgA anti-basement membrane
zone (BMZ) antibodies (Guide and
Marinkovich, 2001). LABD is divided
into two subgroups, lamina lucida–type
and sublamina densa–type, which react
with the epidermal and dermal sides of
1 M NaCl-split normal human skin,
respectively, in indirect immunofluores-
cence (Willsteed et al., 1990).
Most lamina lucida–type LABD sera
react with the 97-kDa and 120-kDa
LAD-1, truncated extracellular domains
of BP180 (Zone et al., 1990; Ishiko
et al., 1996; Ishii et al., 2008). On the
other hand, the autoantigen in sub-
lamina densa–type LABD is still unclear,
although a few cases reacted with
type VII collagen (COL7) in previous
immunoblotting studies (Rusenko et al.,
1989; Zambruno et al., 1994;
Hashimoto et al., 1996).
In this study, we attempted to identify
autoantigen for 12 sublamina densa–
type LABD sera by immunofluorescence
of COL7-lacked recessive dystrophic
epidermolysis bullosa (RDEB) skin and
ELISA of native trimer recombinant pro-
tein of full-length COL7 (Siprashvili
et al., 2010). Materials and Methods
are described in Supplementary
Materials online.
Twelve patient sera were sent to us
from other institutes (11 and one patients
from Japan and Spain, respectively) for
our diagnostic studies. All patients
showed typical clinical, histopathologi-
cal, and immunopathological features.
The results of all immunological
analyses for IgG and IgA antibodies
in the 12 patients are summarized in
Supplementary Table S1 online. Most
patient sera showed negative IgG
reactivity. Only one patient serum
faintly reacted with epidermal side of
1 M NaCl-split skin. In IgA analyses, one
serum showed reactivity with laminin
g2. We speculated that these reactivities
were nonspecific, or these sera had
autoantibodies to multiple antigens.
However, direct immunofluorescence
performed in 11 patients showed only
IgA deposition to BMZ, and indirect
immunofluorescence of normal human
skin detected only IgA anti-BMZ anti-
bodies in 9 patient sera (Table 1). In
addition, 10 sera reacted with dermal
side of 1 M NaCl-split skin, whereas 2
sera reacted with both the epidermal
and dermal sides (Table 1). These results
strongly indicated that the 12 patients
had sublamina densa–type LABD.
In IgA immunoblotting of normal
human dermal extract, three of 12
patient sera and anti-COL7 mAb reacted
with the 290-kDa COL7 (Figure 1a).
Other patient sera and 16 normal con-
trol sera showed no reactivity.
In IgA post-embedding immune-elec-
tron microscopy of normal human skin
section, unexpectedly, all sublamina
densa–type LABD patient sera showed
positive reactivity with the uppermost
dermis at lamina lucida non-visible
areas (Figure 1b, upper) but not at
lamina densa visible areas (Figure 1b,
lower). Epidermolysis bullosa acquisita
serum reacted with lamina densa at
both lamina lucida non-visible and
visible areas (Figure 1e), as reported
previously (Ishii et al., 2004). We specu-
lated that different fixation conditions
during immune-electron microscopy
procedure influenced the access of IgA
Table 1. Summaries of the results of all IgA immunofluorescence,
immunoblotting, and ELISA studies
Patient
no. DIF
IIF of normal
human skin
IIF of 1 M NaCl-
split skin
IIF of
RDEB skin
IB of dermal
extract
ELISA of
COL7 RP
1 BMZþ BMZþ Eþ , Dþ BMZ  0.181
2 BMZþ BMZþ Dþ BMZ  0.229
3 BMZþ BMZþ Dþ BMZ  0.116
4 ND BMZ Dþ BMZ  0.045
5 BMZþ BMZþ Dþ BMZ þ 0.198
6 BMZþ BMZþ Dþ BMZ  0.057
7 BMZþ BMZ Eþ , D± BMZ þ 0.148
8 BMZþ BMZþ Dþ BMZ  0.142
9 BMZþ BMZþ Dþ BMZ  0.079
10 BMZþ BMZþ Dþ BMZþ  0.055
11 BMZþ BMZ Dþ BMZ þ 0.789
12 BMZþ BMZþ Dþ BMZ  0.214
BMZ, basement membrane zone; COL7, type VII collagen; D, dermal side; DIF, direct immuno-
fluorescence; E, epidermal side; IB, immunoblotting; IIF, indirect immunofluorescence; ND, not done;
RDEB, recessive dystrophic epidermolysis bullosa; RP, recombinant protein; þ , positive; ±, weakly
positive;  , negative.
Numbers in italics denote positivity.
Accepted article preview online 10 September 2014; published online 23 October 2014
Abbreviations: BMZ, basement membrane zone; COL7, type VII collagen; LABD, linear IgA bullous
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Figure 1. Immunological analyses of sublamina densa–type linear IgA bullous dermatosis (LABD). (a) Immunoblotting of normal human dermal extract for
12 patient (lanes 1–12) and 16 normal sera (lanes 13–28). Anti-COL7 monoclonal antibody (mAb) reacted with the 290-kDa COL7 (lane P). Red numbers: positive.
(b) Post-embedding immune-electron microscopy (IEM) of normal human skin for Epidermolysis bullosa acquisita (EBA) serum (5 nm gold particles) and
sera from sublamina densa–type LABD patients 1, 2, 5, and 8 (10 nm gold particles). Upper panel: lamina lucida (LL)–invisible. Lower panel: lamina lucida–visible.
Black and white arrows indicate lamina densa and lamina lucida, respectively. Bar¼ 100 nm. (c) Indirect immunofluorescence of normal human and
recessive dystrophic epidermolysis bullosa (RDEB) skin for anti-COL7 mAb, lamina lucida–type LABD serum, and sublamina densa–type LABD sera.
þ : positive reaction to basement membrane zone (BMZ),  : negative reaction to BMZ. Bars¼50mm.
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antibodies in the patient sera. Sera from
patient 5, but not from patients 1, 2,
and 8, reacted with COL7 by immuno-
blotting of the normal human dermal
extract.
We next performed immunofluores-
cence using RDEB skin sections, similar
to a previous study for epidermolysis
bullosa acquisita (Liu et al., 2003). The
results of representative sera are depic-
ted in Figure 1c, and the results of all
sera tested are shown in Supplementary
Figure S1 online. Anti-COL7 mAb
showed no positive reactivity in RDEB
skin, confirming complete lack of COL7
expression (Figure 1c). Anti-laminin g1
pemphigoid patient sera, but not epider-
molysis bullosa acquisita sera, reacted
with BMZ in RDEB skin (data not
shown). Eight of nine sublamina
densa–type LABD sera positive in nor-
mal skin did not react with BMZ in
RDEB skin, whereas a lamina lucida–
type LABD serum reacted with BMZ.
One sublamina densa–type LABD
patient serum (patient 10) reacted with
BMZ on RDEB skin (Figure 1c). None of
the sublamina densa–type LABD sera
negative in normal skin reacted with
BMZ in RDEB skin either.
Although the results of immune-elec-
tron microscopy and immunofluores-
cence of RDEB skin suggested that
most sublamina densa–type LABD
patient sera reacted with COL7, only a
few patient sera reacted with COL7
in immunoblotting of normal human
dermal extract. We considered that
this discrepancy was due to the loss
of conformation of COL7 during the
immunoblotting procedure.
We then performed IgA ELISA using
the commercially available ELISA kit,
which used mammalian recombinant
protein with combined NC1 and NC2
domains of COL7 (Medical and Bio-
logical Laboratories, Nagoya, Japan).
However, in this ELISA, only one patient
serum showed positive reactivity (data
not shown).
Therefore, we developed IgA ELISA.
Trimer form recombinant protein of full-
length mammalian COL7 (Siprashvili
et al., 2010) and Can Get Signal
Immunoreaction Enhancer Solution
(Toyobo, Tokyo, Japan) were used for
detecting autoantibodies to COL7 in
patient sera. The bound autoantibodies
were detected by the HRP detection
system using anti-human IgA-HRP
(Medical and Biological Laboratories,
Nagoya, Japan) and TMB (Moss,
Pasadena, MD). Technical details are
described in Supplementary Materials
online.
In this ELISA, eight sublamina densa–
type LABD patient sera showed positive
results, whereas all 16 normal control
sera were negative (Table 1). Lamina
lucida type–LABD, bullous pemphigoid,
pemphigus vulgaris, and pemphigus
foliaceus sera did not show positive
reaction in the IgA ELISA analyses
(Supplementary Figure S2 online). The
results of this ELISA for three represen-
tative sera at different dilutions indicated
that the results were in a linear range
(Supplementary Figure S3 online). The
different results between commercial
ELISA and developed ELISA in this study
may indicate that IgA autoantibodies in
patient sera reacted with conformational
epitopes in the collagenous domain of
COL7 but not NC1 and NC2 domains.
The results of all studies in this study
are summarized in Table 1. As previous
immunoblotting studies, only 3 of 12
sublamina densa–type LABD patient
sera reacted with COL7 by conventional
immunoblotting of normal human der-
mal extract. In contrast, most patient
sera were confirmed to react with
COL7 by the results obtained in indirect
immunofluorescence of RDEB skin and
ELISA of COL7 trimer recombinant
protein. The results between immuno-
fluorescence and ELISA studies were
almost consistent.
In this study, in addition to three
patients positive with COL7 in conven-
tional immunoblotting, two additional
analyses confirmed the reactivity with
COL7 in five patients, although
autoantigens in four patients were
still unknown. The results in this
study indicated that COL7 is the major
autoantigen in sublamina densa–type
LABD.
All studies were conducted under
the approval of the Ethics Committee
of Kurume University School of
Medicine and according to the
Declaration of Helsinki Principles.
Written informed consent was obtained
from all patients and normal control
individuals.
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TO THE EDITOR
For many years now, researchers have
utilized mouse genetic models to study
various facets of skin biology—from
normal developmental programs to
diseased states. Often, these studies
have included a global examination of
changes in skin gene expression.
Although microarrays have been the
go-to technology in the past, it has been
supplanted by genomic methods driven
by next-generation sequencing (NGS)
such as RNA-sequencing (RNA-seq;
Ozsolak and Milos, 2011). RNA-seq
experiments yield higher throughput
and more precise measurements of
mRNA transcript levels. Hence, a
growing number of studies are now
utilizing RNA-seq to generate transcrip-
tomic maps of cells, tissues, and organs.
Although such studies, particularly
under the auspices of the ENCODE
project, have covered a large number
of biological specimens, to our know-
ledge, data from mouse skin have been
lacking (Stamatoyannopoulos et al.,
2012).
To better appreciate the wide spec-
trum of gene expression levels in
mouse skin, we isolated total RNA from
dorsal skin dissected from 18.5-day-old
embryo (E18.5), post-natal day 3 (P3),
and 10-week-old animals. The RNA
samples, in duplicate, were then sub-
jected to cDNA library preparation
using the TruSeq RNA Sample Prepara-
tion Kit (Illumina) and sequenced in
parallel using an Illumina HiSeq. Reads
were mapped to the reference genome
sequence of Mus musculus (mm9 build),
and transcript read counts were calcu-
lated as fragments per kilobase of tran-
script per million (FPKM) mapped reads.
We next examined the mouse skin
RNA-seq data in detail to probe the
transcriptional regulatory mechanisms
in skin keratinocytes and focused speci-
fically on the transcription factor (TF)
p63. p63 is a member of the p53/p63/
p73 family and a lineage-specific master
regulatory factor highly expressed in
stratified epithelia including the skin
(Crum and McKeon, 2010; Koster,
2010). Mouse knockouts for p63 have
revealed a significant epidermal pheno-
type during embryogenesis (Mills et al.,
1999; Yang et al., 1999; Romano et al.,
2012). However, understanding the
biological role of p63 has often been
hampered by the complexity of the mul-
tiple p63 isoforms generated because of
alternate promoter usage and alternative
splicing (Yang et al., 1998). These p63
isoforms include those possessing a
transactivation domain in the N terminus
(referred to as the TA isoforms) and those
lacking this domain (referred to as the
DN isoforms), as well as three major
splice variants (a, b, and g) that differ in
the C-terminal region (Figure 1). The
complexity of the p63 gene products
has been a source of confusion and
debate over the expression and function
of these isoforms during skin develop-
ment. Our mouse skin RNA-seq data
have offered several key insights into
this topic.
First, consistent with previous studies
(Laurikkala et al., 2006; Romano et al.,
2009), our RNA-seq analysis confirmed
that DNp63 is the primary isoform that is
expressed in mouse skin keratinocytes,
whereas TAp63 isoforms are barely
detectable (Figure 1b and c). Second,
the most abundant transcript identified
in mouse skin is the longer DNp63a
isoform, which encodes for a protein
that is endowed with the sterile alpha
motif (SAM) and transactivation-inhibi-
tory domain (TID) domains. Third,
there exists an isoform that has not
received much attention, which we
have referred to as DNp63D4. This iso-
form is derived from an alternate splice
donor site within exon 8 of the Trp63
gene and encodes for a slightly smaller
protein product, which lacks 4 amino
acids in a segment located between the
DNA-binding and the olimerization
domains of p63 (Figure 1a). Whether
the absence of this 4 amino acids stretch
distinguishes the activity of DNp63aD4
from DNp63a or DNp63gD4 from
DNp63g remains to be seen. Finally,Accepted article preview online 9 September 2014; published online 23 October 2014
Abbreviations: FPKM, fragments per kilobase of transcript per million; NGS, next-generation sequencing;
RNA-seq, RNA-sequencing; NGS, next-generation sequencing; TF, transcription factor
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